Drug Promotions Between Ethics, Regulations, and Financial Interests

• Published in: American journal of therapeutics Vol. 31; no. 3; pp. e268 - e279
• Main Authors: Astărăstoae, Vasile, Rogozea, Liliana M, Leaşu, Florin Gabriel, Roşca, Stefan
• Format: Journal Article
• Language: English
• Published: United States 01-05-2024
• Subjects: Advertising - economics; Advertising - ethics; Advertising - legislation & jurisprudence; Conflict of Interest - economics; Drug Industry - economics; Drug Industry - ethics; Drug Industry - legislation & jurisprudence; Humans; Marketing - economics; Marketing - ethics; Marketing - legislation & jurisprudence
• ISSN: 1075-2765; 1536-3686
• DOI: 10.1097/MJT.0000000000001754

The promotion of the latest medicines produced by the pharmaceutical industry is an important issue both from an ethical point of view (the level of accessibility, the way research is carried out) and from the point of view of marketing and especially from the lobbying issues raised.
The ethical dilemmas raised by the promotion of new drugs revolve between the need to discover new molecules important for treating a wide range of diseases and the need to establish a battery of ethical rules, absolutely necessary for regulations in the field to be compliant with all ethical principles.
A literature search was conducted through PubMed, MEDLINE, Plus, Scopus, and Web of Science (2015-2023) using combinations of keywords, including drugs, medical publicity, and pharma marketing plus ethical dilemma.
The promotion of medicines is governed by advertising laws and regulations in many countries, including at EU level, based on the need for countries to ensure that the promotion and advertising of medicines is truthful, based on information understood by consumers. The ethical analysis of the issues raised is more necessary and complex as the channels used for promotion are more accessible to the population, and the information, easier to obtain, can be the cause of increased self-medication and overeating. Large amounts of money invested in the development of new molecules, but also the risk of scientific fraud through manipulation of data during clinical trials, selective or biased publication of information can have repercussions on the health of the population.
The development of new pharmaceutical molecules is necessary to intervene and treat as many conditions as possible, but marketing must not neglect the observance of ethical principles. The promotion of medicines should be the attribute especially of the medical staff, which should also be a mandatory part of the mechanism for approving the marketing methods and means used by the pharmaceutical companies.